Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally

Executive Summary

Sandoz has begun a global Phase III trial with its biosimilar version of Amgen's Enbrel (etanercept), targeting psoriasis rather than the more lucrative indication for rheumatoid arthritis, with the aim of winning quicker regulatory approval which can be built on as it gains insights testing the medicine.

Advertisement

Related Content

Sandoz Still Trying To Sneak Past Amgen’s Stealth Enbrel Patents
Pfizer’s Xeljanz In Psoriasis Does Best At Dose That Worried FDA
Pfizer’s Xeljanz In Psoriasis Does Best At Dose That Worried FDA
Hospira’s Inflectra, EU’s First Biosimilar mAb, Will Challenge Skeptics
Deals Of The Week: Hunting For Dengue Fever Drugs Amid Climate Change
Breast Cancer Protection Plan In Place, Roche Turns Attention To Hematology
Managing The World’s First Blockbuster Generic: An Interview With Sandoz’s George
Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics
FDA, EMA Seek Biosimilar Pathway Convergence

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel